References
- Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Exp Rev Clin Pharmacol 2015;8(1):77-94
- Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 2014;5:109
- Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority medicines for europe and the world. 2013. Available from: www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1
- WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Available from: www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research
- Piperska group rational prescribing home page. Available from www.piperska.org/home
- The agency for health technology assessment and tariff system (AOTMiT) Home Page. Available from: www.aotm.gov.pl/www/index.php?id=397
- EFPIA. HEALTH & GROWTH - Evidence compendium. Available from: www.efpia.eu/uploads/Modules/Documents/health-and-growth_evidence-compendium.pdf [Last accessed 30 October 2013]
- Gustafsson LL, Wettermark B, Godman B, et al. The ’wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic clin Pharmacol Toxicol 2011;108(4):224-33
- Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Europ J Clin Pharmacol 2013;69(Suppl 1):73-8
- Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC health Ser Res 2010;10:128
- Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013;4:39
- Joppi R, Pase D, Poggiani C. Italian horizon scanning project. G Ital Health Technol Assess 2013;6:11-21
- Cochrane handbook for systematic reviews of interventions version 5.1.0. Available from: http://handbook.cochrane.org/
- Scottish medicines consortium. guidance to manufacturers for completion of new product assessment form (NPAF). Available from: www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission 2014
- NHS lothian pharmacy strategy 2013–2016. Available from: www.nhslothian.scot.nhs.uk/OurOrganisation/Consultations/Current/Documents/PharmacyStrategy.pdf
- Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Exp Rev Phar Out Res 2012;12(4):439-41
- Wettermark B, Zoega H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf 2013;22(7):691-9
- Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol 2015;116(2):146-57
- Furst J, Cizman M, Mrak J, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Exp Rev Anti Infect Ther 2015;13(2):279-89
- 19th WHO. Model list of essential medicines. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf?ua=1 2015
- Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium–the just price. J Clin Oncol 2013;31(28):3600-4
- Mack A. Norway, biosimilars in different funding systems. What works? Gen Bios Initiat (GABI) J 2015;4(2):90-2